A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease

Autor: Lawrence Elmer, McGuire D, Janis M. Miyasaki, Pierre N. Tariot, Cynthia L. Comella, Rajesh Pahwa, S. Schuman, Margaret C. Lannon, James W. Tetrud, Wiener W, Christopher Cox, Oksana Suchowersky, Wratni E, Lucia M. Blasucci, Chase T, Greenamyre Jt, Karen Hodgeman, Deleo A, Michael P. McDermott, Carrion A, Panniset M, Paula D. Ryan, Robert A. Hauser, Johnston L, Bateman-Rodriguez D, Amy Colcher, Baker D, Mistura K, Andrew Siderowf, W.R. Wayne Martin, Peggy Gray, Constance Orme, Jeffrey Friedlander, Charles H. Adler, Dilllon S, Stanley Fahn, Eric Siemers, David Grimes, Lauren Seeberger, M. Brewer, Colleen Dingmann, Frey J, Holdich T, Cooper J, Mark Stacy, Stewart A. Factor, Daniel Tarsy, Kennedy L, McCree L, Mary Lloyd, J. B. Penney, Lisa Gauger, Pantella C, Arthur Watts, Kenneth Marek, John P. Hammerstad, Matthews M, Kimberly Janko, Diane Brown, Denni Day, McDermott J, Sulimowicz K, Ruzicka D, Marsha Tennis, Bardram K, Joann Belden, Madaline B. Harrison, Blair Ford, Davies R, Mark F. Lew, Alderfer, Jennifer Mazurkiewicz, Elise Kayson, Broshjeit S, Rexo L, Andrew Feigin, Craun Am, Cha Jh, C. Stone, Stephanie Newman, Nirupama Laroia, Jean Hall, Ira Shoulson, Peter A LeWitt, Read B, Robert L. Rodnitzky, Danna Jennings, Judith Dobson, Lang A, Florack M, Nobel R, Steven R. Schwid, Leventhal C, A. L. Lafontaine, Nancy Pearson, Lawrence N. Shulman, Rothenburgh K, Rost E, Locke B, Cindy Casaceli

Publikováno v: Neurology. 56:455-462

Background Preclinical studies suggest that glutamate antagonists help ameliorate motor fluctuations in patients with PD treated with levodopa. Methods In a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d568a8ad50ad99173f553a65cfb0dde5
https://doi.org/10.1212/wnl.56.4.455

The selective muscarinic M1 agonist AF102B decreases levels of total A? in cerebrospinal fluid of patients with Alzheimer's disease

Autor: Meihua Deng, John H. Growdon, Marsha Tennis, Roger M. Nitsch, David A. Schoenfeld

Publikováno v: Annals of Neurology. 48:913-918

beta-Amyloid (Abeta) deposits in diffuse and compact senile plaques in the brain are one of the defining histopathological features of Alzheimer's disease (AD). Preventing Abeta deposition is a goal of drug therapy for AD, because excessive amounts o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b945865a15ce01c67ff9d726b6ce8e8
https://doi.org/10.1002/1531-8249(200012)48:6<913::aid-ana12>3.0.co

Environment-driven responses in progressive supranuclear palsy

Autor: Marsha Tennis, Keith A. Johnson, John H. Growdon, Eric P. Hoffman, J. Ghika

Publikováno v: Journal of the Neurological Sciences. 130:104-111

The neurological signs and behaviors that accompany degenerative diseases associated with fronto-striatal dysfunction are incompletely described. We observed several novel environmentally-driven behaviors in seven patients with progressive supranucle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a382a6e410b01980e87fc1f1e795bc45
https://doi.org/10.1016/0022-510x(95)00015-t

Urate predicts rate of clinical decline in Parkinson disease

Autor: Stanley Fahn, Arthur Watts, Karl Kieburtz, Kui Xu, Peter A. LeWitt, Alberto Ascherio, Mikhail B. Bogdanov, Anthony E. Lang, Michael A. Schwarzschild, M. Flint Beal, Marsha Tennis, David Oakes, Connie Marras, Shirley Eberly, Wayne R. Matson, Caroline M. Tanner, Steven R. Schwid, Alice Rudolph, Ira Shoulson

Background The risk of Parkinson disease (PD) and its rate of progression may decline with increasing concentration of blood urate, a major antioxidant. Objective To determine whether serum and cerebrospinal fluid concentrations of urate predict clin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a532bd64fb46ada8cfdc545768918d9
https://europepmc.org/articles/PMC2795011/

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease

Autor: Arthur Watts, Blair Ford, Marsha Tennis, Ronald F. Pfeiffer, Jean P. Hubble, Cliff Shults, Mickie Welsh, John Seibyl, Carolyn Weeks, Sandra Dillon, John P. Hammerstad, Amy Montgomery, Stewart A. Factor, Farah Atassi, William J. Weiner, Barbara Alexander-Brown, Karl Kieburtz, Roger Kurlan, David S. Russell, Stanley Fahn, Ali H. Rajput, Jean Hall, Ira Shoulson, Brenda Pfeiffer, Bruno Musch, Karen Richard, Deborah Fontaine, David G. Standaert, Kevin M. Biglan, Mark Stacy, Debra Berry, Frederick Wooten, Diane Brown, Michael P. McDermott, Tori Ross, Giselle Petsinger, Theresa Shirley, Susan E. Bennett, Leona Borchert, Kenneth Marek, Laura Sutherland, Rajesh Pahwa, Janis M. Miyasaki, Susan Wood, Robert G. Holloway, Cornelia Kamp, Sharon Evans, Pamela Rainey, Anthony E. Lang, Michel Panisset, Elspeth Sime, Carol Pantella, Susan Daigneault, Barbara Fussell, Carolynn O'Connell, Joseph Jankovic, Aileen Shinaman, Elke Rost-Ruffner, Peter A. LeWitt, Alicia Brocht, Karen Hodgeman, Cheryl Waters, Mary Harrigan, Robert L. Rodnitzky, Judith Dobson, David E. Riley, Oksana Suchowersky, Maryan DeAngelis, Lynn Barclay

Publikováno v: Archives of Neurology. 61

BACKGROUND The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. OBJECTIVE To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416eb9465f792702da6023996d72d71f
https://doi.org/10.1001/archneur.61.7.1044